1. GPCR/G Protein
    Neuronal Signaling
    Immunology/Inflammation
  2. 5-HT Receptor
    Histamine Receptor
    Adrenergic Receptor
  3. Mirtazapine

Mirtazapine (Synonyms: Org3770; 6-Azamianserin)

Cat. No.: HY-B0352 Purity: 99.97%
Handling Instructions

Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a 5-HT2, 5-HT3, histamine H1 receptor and α2-adrenoceptor antagonist with pKi values of 8.05, 8.1, 9.3 and 6.95, respectively.

For research use only. We do not sell to patients.

Mirtazapine Chemical Structure

Mirtazapine Chemical Structure

CAS No. : 85650-52-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 207 In-stock
Estimated Time of Arrival: December 31
100 mg USD 188 In-stock
Estimated Time of Arrival: December 31
200 mg USD 319 In-stock
Estimated Time of Arrival: December 31
500 mg USD 569 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Mirtazapine:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a 5-HT2, 5-HT3, histamine H1 receptor and α2-adrenoceptor antagonist with pKi values of 8.05, 8.1, 9.3 and 6.95, respectively[1][2].

IC50 & Target[2]

5-HT3 Receptor

8.1 (pKi)

5-HT2 Receptor

8.05 (pKi)

H1 Receptor

9.3 (pKi)

α2-adrenergic receptor

6.95 (pKi)

In Vitro

Mirtazapine can antagonize the adrenergic α2-autoreceptors and α2-heteroreceptors as well as block 5-HT2 and 5-HT3 receptors. Mirtazapine enhances the release of norepinephrine and 5-HT1A-mediated serotonergic transmission[1].
The cytochrome (CYP) P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4 are mainly responsible for Mirtazapine's metabolism[1].
Mirtazapine (10 μM) significantly reduces activation-induced release of cytokine/chemokine mediators from human CD14+ monocytes in vitro[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mirtazapine (1-20 mg/kg; intraperitoneal injection; once; C57BL/6 mice) treatment strikingly and dose-dependently inhibits Con A-induced liver injury[3].
Mirtazapine treatment inhibits hepatic macrophage/monocyte activation, decreases hepatic macrophage/monocyte-derived pro-inflammatory cytokine (e.g., TNFα) and chemokine (e.g., CXCL1 and CXCL2) production, suppression of Con A-induced increases in the hepatic expression of the neutrophil relevant endothelial cell adhesion molecule ICAM-1, with the resultant significant reduction in neutrophil recruitment into the liver[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (8-10 week old) treated with concanavalin A (Con A)[3]
Dosage: 1 mg/kg, 10 mg/kg, and 20 mg/kg
Administration: Intraperitoneal injection; once
Result: Strikingly and dose-dependently inhibited Con A-induced liver injury.
Clinical Trial
Molecular Weight

265.35

Formula

C₁₇H₁₉N₃

CAS No.

85650-52-8

SMILES

CN1CC2C3=CC=CC=C3CC4=CC=CN=C4N2CC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (188.43 mM; Need ultrasonic)

H2O : 0.67 mg/mL (2.52 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7686 mL 18.8430 mL 37.6861 mL
5 mM 0.7537 mL 3.7686 mL 7.5372 mL
10 mM 0.3769 mL 1.8843 mL 3.7686 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

MirtazapineOrg3770 6-AzamianserinOrg 3770Org-37705-HT ReceptorHistamine ReceptorAdrenergic ReceptorSerotonin Receptor5-hydroxytryptamine ReceptorBeta ReceptorAntidepressantoralnoradrenergicserotonergic5-HT25-HT3autoimmuneTNFαα2-adrenoceptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mirtazapine
Cat. No.:
HY-B0352
Quantity:
MCE Japan Authorized Agent: